Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 6Hot Flashes 3Risk Reduction Behavior 1Prostatic Neoplasms 1Osteoporosis 1Focus of Study is Healthy Women at Risk for Breast Cancer 1Endometrial Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Breast Carcinoma In Situ 1

Interventions

Docetaxel 277Prednisone 237enzalutamide 177Leuprolide 172Radiotherapy 164Abiraterone Acetate 154Magnetic Resonance Spectroscopy 147bicalutamide 137Goserelin 134Androgen Antagonists 111Radiosurgery 101acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100apalutamide 79abiraterone 77gallium 68 PSMA-11 74Specimen Handling 67darolutamide 58Gonadotropin-Releasing Hormone 58Radiation 56Triptorelin Pamoate 53cabazitaxel 50Zoledronic Acid 49pembrolizumab 48Radiotherapy, Intensity-Modulated 47Flutamide 47Brachytherapy 47luprolide acetate gel depot 46Standard of Care 45Carboplatin 44Estramustine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Prostatic Neoplasms × Estrogens, Conjugated (USP) × Clear all
NCT00134654 2011-06-16

Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
48 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡